Five things for pharma marketers to know: Monday, August 21, 2017
1. The FDA approved Ironwood's new gout treatment, Duzallo. Ironwood CEO Peter Hecht expects the drug to bring in more than $300 million in annual sales. (Endpoints News)
2. Some patient and provider groups are opposed to the American Society of Clinical Oncology's policy recommendation to only approve cancer drugs if they produce a “clinically meaningful” benefit, rather than drugs that simply achieve “statistical significance.” Friends of Cancer Research, the Community Oncology Alliance, and the Association of Community Cancer Centers said this policy, if enacted, would cut access to therapies that provide benefits not captured by stats like overall survival. (BioCentury)
3. McCann Health North America promoted Jesse Johanson to president of McCann Echo, replacing Sonja Foster-Storch who has been named president of GSW North America. McCann Health North America said that it has promoted Jesse Johanson to replace her as president of McCann Echo.
4. Samsung Bioepis and Takeda will partner to co-develop new biologics. The first candidate to be co-developed is an experimental drug for severe acute pancreatitis.
5. ICYMI: HIV diagnosis rates at two sexual health centers in London and San Francisco have dropped significantly since the approval of Gilead Sciences' Truvada, a pill that reduces the risk of HIV from sex by more than 90%. Sales of Truvada reached $3.5 billion in 2016. (Bloomberg)
Correction: An earlier version of this article incorrectly described Sonja Foster-Storch's new title. It is president.